Scienmag

SEPTEMBER 13, 2021

Philadelphia, September 13, 2021—Researchers at Children’s Hospital of Philadelphia (CHOP) have demonstrated that an experimental device can improve blood sugar control in patients who developed diabetes after their pancreas was removed to treat their hyperinsulinism, a genetic disease in which the pancreas produces too much insulin.

Genetic Disease 52

Genetic Disease Insulin Hormones Research 52

XTalks

SEPTEMBER 14, 2022

Hear more about the rare, fatal disease and the new drug approval for it. Ayesha also talked about Medtronic’s new partnership with former Disney star Jennifer Stone on a new ad campaign for its diabetes tech, including the smart insulin injector InPen.

Life Science 90

Life Science FDA Approval Insulin Drugs 90

pharmaphorum

AUGUST 24, 2021

It seems likely that the type 1 diabetes programme will be focused on developing cells that can secrete insulin in response to blood glucose levels – acting as a replacement for pancreatic beta cells that are destroyed in the autoimmune disease – which is already a focus of Vertex’ research.

Gene Editing 52

Gene Editing Gene In-Vivo Genetics 52

XTalks

SEPTEMBER 17, 2020

Acromegaly Surrogate Endpoint: Serum growth hormone and serum insulin-like growth factor 1 (IGF-1) are acceptable surrogate endpoints for acromegaly clinical trials involving somatostatin analogs such as octreotide, lanreotide and pasireotide. Also known as Berardinelli-Seip syndrome, there are four subtypes of lipodystrophy.

Trials 98

Trials Gene Hormones Clinical Trials 98